Expression of recombinant mature lysostaphin
CA 2388003 C · Owner: Bharat Biotech International, Ltd. · Inventors: Sharma, Rahul; Khatri, Ghan Shyam
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A portion of the lysostaphin gene of Staphylococcus simulans has been cloned and overexpressed in the cytoplasm of E.coli to yield mature lysostaphin in , the absence of preprolysostaphin and prolysostaphin under the transcriptional , control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed does not require posttranslational modification. The mature lysostaphin so formed can be used to treat and prevent staphylococcal infections.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 19, 1999 and granted February 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 19, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 19, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.